Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 21, 20 December 2023
Open
Access | Article
Applications of the CRISPR-Cas9 system in cancer models
* Author to whom correspondence should be addressed.
Abstract
Cancer has a high mortality and prevalence rate in the world. CRISPR-Cas9 is one of the novel and most common gene-editing techniques. Compared with the first two generations of gene-editing technologies, CRISPR-Cas9 system has the advantages of easy design, low cost, high efficiency and so on. sgRNA guides Cas9 to the site of the targeted gene, and Cas9 cuts the DNA strand at that site, triggering the NHEJ or HDR mechanism so as to achieve the purpose of deletion or insertion. CRISPR-Cas9 can be combined with other factors for other purposes, such as CRISPRa, CRISPRi, and base editing. The CRISPR system now has been used extensively for research into biological mechanisms and disease treatments. Since cancer is controlled by genes, a number of researchers in recent years have looked at using the CRISPR system to treat cancer. The CRISPR technology has greatly improved our understanding of cancer and the factors that affect it, and has had a major impact on the study and treatment of cancer. CRISPR gene editing can quickly and efficiently generate gene knockouts and regulate gene expression to identify relevant genes that influence cancer growth. This review systematically introduces CRISPR-Cas9 and its application methods, delivery modes, and discusses some studies using cell lines and organoids in vitro and animal models for cancer therapy in vivo.
Keywords
CRISPR-Cas9, cancer, therapy, model
References
1. Ferlay J, et al. (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today
2. “The Genetics of Cancer.” National Cancer Institute, 17 Aug. 2022, www.cancer.gov/about-cancer/causes-prevention/genetics.
3. ZHENG Wu, GU Feng. Research progress on application and off-target effect of CRISPR/Cas9[J].Heredity,2015,37(10):1003-1010.
4. Jinek, Martin, et al. “A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive. Bacterial Immunity.” Science, vol. 337, no. 6096, American Association for the Advancement of Science, 17 Aug. 2012, pp. 816–21.
5. Gleditzsch, Daniel, et al. “PAM Identification by CRISPR-Cas Effector Complexes: Diversified. Mechanisms and Structures.” RNA Biology, vol. 16, no. 4, Taylor and Francis, 3 Apr. 2019, pp. 504–17.
6. Tan, Jun-Jie, et al. “DNA Base Editing in Nuclear and Organellar Genomes.” Trends in Genetics, vol. 38, no. 11, Elsevier BV, 1 July 2022, pp. 1147–69.
7. Heidersbach, et al. A versatile, high-efficiency platform for. CRISPR-based gene activation. Nat Commun 14, 902 (2023).
8. Genomics, Sigma-Aldrich® Advanced. “Why You Should Consider Adding CRISPRa and. CRISPRi to Your Toolbox.” Bitesize Bio, 27 May 2020.
9. Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451 (2013). Along with Qi et al., this paper describes the use of Cas9 for targeted control of transcriptional activation and repression.
10. Mirabelli, Peppino, et al. “Cancer Cell Lines Are Useful Model Systems for Medical Research.” Cancers, vol. 11, no. 8, MDPI, 1 Aug. 2019, p. 1098.
11. Yang Yang, et al . “KRAS Mutation: From Undruggable to Druggable in Cancer.” Signal Transduction and Targeted. Therapy, vol. 6, no. 1, Nature Portfolio, 15 Nov. 2021,
12. GAO Meng, ZHAI Nailiang. Role of Keap1/Nrf2 in treatment resistance of non-small cell lung cancer[J].Journal of Binzhou Medical College,2022,45(06):467-471.
13. Wang Li. Preparation of sgRNA and CRISPR/Cas9 by overlapping primer PCR for EGFR deletion mutation enrichment in lung cancer ctDNA[D].Southern Medical University,2021.
14. He, Chenglong. “CRISPR Screen in Cancer: Status Quo and Future Perspectives.” PubMed Central (PMC), 2021,
15. WANG Haixia, ZHANG Cong, ZOU Dongling. Application of organoid model in precision diagnosis and treatment of tumors[J].Chinese Clinical Oncology,2023,50(06):291-295.
16. Geurts, Maarten H., and Hans Clevers. “CRISPR Engineering in Organoids for Gene Repair and Disease. Modelling.” Nature Reviews Bioengineering, vol. 1, no. 1, 19 Jan. 2023, pp. 32–45..
17. HU Kun, LIU Yuhan, XIAO Junwen, LIAO Xinhui, CHEN Jieqing,ZHANG Zhongfu,WU Jianting,MEI Hongbing. Progress of CRISPR/Cas9 gene editing technology in prostate cancer research[J].Life Science,2019,31(07):731-738.
18. Cancer Belong to Consensus Molecular Subtype 4 and Are Sensitised to Oxaliplatin by Inhibiting Reducing. Capacity.” British Journal of Cancer, vol. 126, no. 12, Nature Portfolio, 22 Feb. 2022, pp. 1824- 33.
19. LI Yaona, YANG Huiyu. Research progress of TP53-induced glycolysis and apoptosis regulators in common cardiovascular diseases[J].China Medical Journal,2023,18(04):599-602.
20. Huang, Lamei, et al. “KRAS Mutation: From Undruggable to Druggable in Cancer.” Signal Transduction and. Targeted Therapy, vol. 6, no. 1, Nature Portfolio, 15 Nov. 2021.
21. DENG Yichen, LIU Yunbo. Research progress of AAV vector targeted modification strategy in gene therapy[J].Chinese Journal of Comparative Medicine,2017,27(02):81-85.
22. Dai, Meiou, et al. “In Vivo Genome-wide CRISPR Screen Reveals Breast Cancer Vulnerabilities and Synergistic. mTOR/Hippo Targeted Combination Therapy.” Nature Communications, vol. 12, no. 1, Nature Portfolio, 24 May 2021.
23. M, Martinez-Lage, et al. “In Vivo CRISPR/Cas9 Targeting of Fusion Oncogenes for Selective Elimination of. Cancer Cells.” Nature Communications, vol. 11, no. 1, Nature Portfolio, 8 Oct. 2020.
24. Thomsen, Martin K. “Application of CRISPR for in Vivo Mouse Cancer Studies.” Cancers, vol. 14, no. 20, MDPI, 13 Oct. 2022, p. 5014.
25. Hou, Xucheng, et al. “Lipid Nanoparticles for mRNA Delivery.” Nature Reviews Materials, vol. 6, no. 12, Nature. Portfolio, 10 Aug. 2021, pp. 1078–94.
26. Pardi, Norbert, et al. “mRNA Vaccines — a New Era in Vaccinology.” Nature Reviews Drug Discovery, vol. 17, no. 4, Nature Portfolio, 12 Jan. 2018, pp. 261–79.
27. Rosenblum, Daniel, et al. “CRISPR-Cas9 Genome Editing Using Targeted Lipid Nanoparticles for Cancer. Therapy.” Science Advances, vol. 6, no. 47, American Association for the Advancement of Science, 18 Nov. 2020.
28. Ahmadi, Seyed Esmaeil, et al. “Viral Vectors and Extracellular Vesicles: Innate Delivery Systems Utilized in. CRISPR/Cas-mediated Cancer Therapy.” Cancer Gene Therapy, Springer Nature, 28 Feb. 2023.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-215-2
- ISBN (Online)
- 978-1-83558-216-9
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/21/20230804
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited